Filing Flows › iSpecimen (ISPC) › Q1 2026 › vs Q4 2025
iSpecimen (ISPC) Q1 2026 vs Q4 2025 (quarter over quarter)
iSpecimen's revenue rose $104K (+201%) from $52K in Q4 2025 to $156K in Q1 2026.
iSpecimen, Q1 2026: revenue $156K (-85% year over year), net loss $2.3M, operating cash flow −$3.4M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $156K | $52K | $104K | +201% |
| Other income, net | $263K | −$2.3M | $2.6M | — |
| Net loss | $2.3M | $5.0M | −$2.7M | -55% |
| Costs & expenses | $2.7M | $5.1M | −$2.4M | -47% |
| Operating costs | $2.7M | $2.7M | −$45K | -2% |
| Cost of revenue | $84K | $551K | −$467K | -85% |
| Sales & marketing | $1.5M | $549K | $993K | +181% |
| General & admin | $680K | $901K | −$221K | -24% |
| Other operating costs | $387K | $738K | −$351K | -48% |
| Operating cash sources | $3.5M | $1.3M | $2.2M | +164% |
| Depreciation & amortization | $136K | $408K | −$272K | -67% |
| Share-based compensation | $1K | $2K | −$1K | -42% |
| Cash used in operations | $3.4M | $917K | $2.4M | +267% |
| Net loss absorbed | $2.3M | $5.0M | −$2.7M | -55% |
| Working capital & other | $1.2M | −$3.7M | $4.9M | — |
Questions
How much did iSpecimen's revenue grow quarter over quarter in Q1 2026?
iSpecimen's revenue rose $104K (+201%) from $52K in Q4 2025 to $156K in Q1 2026.